Webinar Recording

Critical Considerations for Mergers & Acquisitions

Legal and regulatory overview on due diligence

On-Demand 1 Hour Your Desk!

REGISTER NOW

**For more information, please see Cencora PharmaLex Privacy Policy. If you do not wish to receive any communication from us, you may unsubscribe at any time.

Speakers

John Cahill

Director, Senior Consultant, Q&C,PharmaLex

Richard Phillips

Partner & Corporate Lawyer, VWV

Anna Geist

Director, Head of Regulatory & Special Projects, PharmaLex

2021 started with stellar news as Sanofi agreed to acquire British biotech Kymab for around $1.45 billion. It is a chequered flag for the start of this seasons M&A activity for Life Sciences companies. Great expectations? This fast-growing sector comprises pharma, biotech, cell & gene therapy, medical device and diagnostics amongst all. Corporations must take expert legal and regulatory advice in addition to financial due diligence.

PharmaLex and VWV ponder legal and regulatory solutions for supporting M&A deals, takeovers, business moves, leveraging, spin-outs, carve-outs and strategic partnerships.

Key learnings:

  • Discover just when to involve legal and regulatory experts in an M&A process
  • Good appreciation of the roles played by dedicated legal, regulatory and quality experts in M&A
  • Be made aware of critical considerations around the pivot point: Due Diligence
  • Hear about the 6th stage of M&A -Rescue, too often forgotten
Download The free eBook